New study investigates blood clot risks in Kids' leukemia treatment

NCT ID NCT07071051

First seen Nov 01, 2025 · Last updated Jun 17, 2026 · Updated 30 times

Summary

This study looks at how the chemotherapy drug calaspargase pegol (Cal-PEG) affects blood clotting in children with acute lymphoblastic leukemia (ALL). Researchers will take blood samples before and after treatment to measure changes in coagulation. The goal is to better understand and manage clotting side effects in young patients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Mayo Clinic in Rochester

    RECRUITING

    Rochester, Minnesota, 55905, United States

    Contact Email: •••••@•••••

    Contact

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia childhood acute lymphoblastic leukemia lymphoblastic lymphoma Precursor Cell Lymphoblastic Leukemia-Lymphoma T-cell childhood lymphoblastic lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.